Member Info for HelloSanDiego

Also, that 100% price rise in mid-April happened a week before it was announced Abatacept would be added to STRIVE.

I doubt that was a coincidence.

Thanks for the help Wigster.

I see that the second drug they added (abatacept) was also originally on ACTIV, just like the Shionogi drug they started with. I looked at the STRIVE selection criteria last year and remember posting that, although I didn't think ours would qualify as the very strongest candidate, it looked like it could be in the top two or three. So here's hoping.

Abatacept STRIVE trial page, for reference:

https://classic.clinicaltrials.gov/ct2/show/NCT05822583?term=STRIVE&draw=2&rank=8

I haven't checked back here in a few months but I just noticed there was a big price rise in mid-April. Can anybody tell me what happened?

Also, what's the latest on Strive, and have there been any significant changes regarding major shareholders (buys or sells) in the past few months?

Thanks.

I'm not sure if this has already been posted. But it looks like any official updates will appear here:

https://www.niaid.nih.gov/clinical-trials/strategies-treatments-respiratory-infections-viral-emergencies

Thanks Gunto. I've been searching for firm news about STRIVE for months and it's been few and far between. So it's good to see NIH publicly addressing it.

On 7th November TommyD posted an email on here he claimed was a conversation he was having with Dr. Stacey Adam who reportedly said: "Further agents are in process for STRIVE".

That suggests that more than one additional drug is in the process of being added to STRIVE.

That's my point, Axe.

You appear to have missed it, so I'll explain it in words of only one syllable: In two-oh-two-oh lots of us got sick so the white coats had to move more fast than they used to. But now things have calmed down so the pace is less fast. You see now?

A lot of the whiners on here don't seem to understand that pharmaceutical investing normally works at a glacial pace.

A year without any news is not unusual for a small drug discovery firm, and inconclusive results (like SPRINTER) are a delay rather than a failure. You can do everything right and they can still occur, even if the drug actually works.

Aether - "Out of interest, what would it cost them for you to hand your shares over?"

If they want to buy the entire company it means they're confident it will be worth billions in a few years and are probably expecting a new trial to be paid for for us. The previous target of £10 to £50 a share is still achievable in the next three to five years, but only if we get on a platform trial in the next 12 months. So anything less than £1 would be an insult.

I'd begrudgingly agree to £2 but I don't think they'll go anywhere near that. So I think I'll be voting 'no' anyway, even though I'm sure any offer would be at or above break-even for me.

It's possible they intend to put in a bid for the rest of the company if they let it drop below 10p.

If that's the plan, it would be silly to push the price up to 15p or 20p just to pick up another 1.8% right now.

Ashfield Engage says it has over 5000 employees. So it's entirely possible they need another Medical Affairs director and just agreed to attach Synairgen to it in the ads to make the company look good.

But with all these new roles it definitely looks like they either a) have the nod they'll be on another trial soon, or b) are intentionally making it appear that way.

I'm pretty confident we can rule out 'hiring new staff just in case'. When they did that before, it was when they were *expecting* good news and had the cash to able to afford 'just in case' recruitment and expenditure.

Thanks Doc.

Has there been any more news on the new roles advertised in mid-November last year? The Director of Quality and Clinical Project Manager roles looked like a promising hint of an upcoming trial.

Going by the selection criteria they used for deciding which agents to prioritise for STRIVE, I still think we looked likely to be in the top 3 or 4. So unless that's changed, my main concern is the company running out of money before STRIVE adds more drugs.

I haven't heard of that. Is it another platform trial? Nothing's coming up when I search 'Jenson covid trial'.

STRIVE still looks like offering our only chance of things turning around in the next few years, unless another large platform trial emerges.

Does anyone know how long the company has until it runs out of money, and have they announced any significant cost-cutting measures yet?

MrCosts - "SNG001 has not been used in a trial setting since November 2021"

And that's it? You think that proves that there's no interest in the drug?

MrCosts - "The strongest signal for SNG001 is that no one is really interested."

Do you think that very few trades means there is no interest?

Delboy - "is it possible SNG may have the nod to be on STRIVE but the NIH want to have proof the company will be funded to finish it? After all it could be running for what 12-18 months."

I don't think so. If it gets on STRIVE the company shouldn't have a problem raising enough money to survive until the trial ends. They already have enough of the drug to complete the trial.

Besides, even if the company folds, someone will pick up the patent and manufacture it if the drug works.

Re: STRIVE

Tommy D said on 7th November he'd received an email from Dr Stacey Adam where she claimed:

"Further agents are in process for STRIVE; however, I am not able to discuss what these agents are. One note for your reference though is STRIVE is an inpatient trial and ACTIV-2 was focused on outpatients; therefore, not every agent will be relevant for both populations"

I can't be certain but I'm inclined to believe he wasn't making that up.

I also looked at the STRIVE selection criteria from last year and was sceptical that SNG would be the top of the list, but would be very likely to appear in the top 3. All of that's my opinion though. Do your own research.

Until they announce the new drugs that are due to be included on STRIVE, there's still a chance this won't have been a complete loss for most of us here.

If we're on a new trial by then, I don't think they'll want to dilute their own shareholding unnecessarily.

So there's no guarantee a fundraise will even happen.